Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives $55.25 Consensus Target Price from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has earned an average rating of “Moderate Buy” from the seventeen research firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $55.25.

Several research firms have recently issued reports on KYMR. Stifel Nicolaus began coverage on shares of Kymera Therapeutics in a report on Tuesday, May 20th. They issued a “buy” rating and a $55.00 target price for the company. HC Wainwright raised their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Wall Street Zen upgraded shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Guggenheim restated a “buy” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a report on Monday, May 12th. Finally, Citigroup initiated coverage on shares of Kymera Therapeutics in a research note on Thursday, March 13th. They issued a “buy” rating and a $52.00 price target on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in KYMR. Blue Trust Inc. increased its position in Kymera Therapeutics by 74.8% during the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the period. State of Wyoming purchased a new position in Kymera Therapeutics during the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new position in Kymera Therapeutics during the 4th quarter valued at about $55,000. KBC Group NV grew its position in shares of Kymera Therapeutics by 15.2% in the 1st quarter. KBC Group NV now owns 2,479 shares of the company’s stock worth $68,000 after buying an additional 328 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new position in shares of Kymera Therapeutics in the 1st quarter worth approximately $68,000.

Kymera Therapeutics Stock Down 2.6%

KYMR stock opened at $29.46 on Wednesday. Kymera Therapeutics has a 52 week low of $19.45 and a 52 week high of $53.27. The company has a fifty day simple moving average of $28.58 and a two-hundred day simple moving average of $35.58. The firm has a market capitalization of $1.92 billion, a P/E ratio of -12.59 and a beta of 2.18.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.10. The firm had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business’s revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.69) EPS. As a group, analysts anticipate that Kymera Therapeutics will post -2.79 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.